TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT06704347: Safety Study of XT-150 in Participants With ALS

Sponsor: Xalud Therapeutics, Inc. · Phase: PHASE1 · Area: RARE_ORPHAN · Target Enrollment: 20 pts

Competing Trials Overlap

5 Active Trials

Excess Burn Exposure

$945,540

Rescue Site Savings

+$630,360

Unlock Full NCT06704347 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06704347 Rescue Dossier →